Health Boards
Thu-30-09-2021, 17:11 PM
That is looking good for Bimzelx. Right on the market and then already this supporting study.
Also it seems that the detailed targeting is positive for the side effects and the endurance.
The interesting thing is that they are targeting IL-17, which is often more associated with Psoriatic Arthritis, then with psoriasis.. So certainly for those with Psoriatic Arthritis this holds a promise for when it is given free for this group.
Also it seems that the detailed targeting is positive for the side effects and the endurance.
The interesting thing is that they are targeting IL-17, which is often more associated with Psoriatic Arthritis, then with psoriasis.. So certainly for those with Psoriatic Arthritis this holds a promise for when it is given free for this group.
